Payment overview · 2025
General Payments
$136.32
7 reported records · 4 companies
Healthcare provider profile · identity verified
Jamie Bennett
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ASHLAND, KY · NPI 1346615473
Verified facts
What the public records show
CMS Open Payments records show Jamie Bennett received $136.32 in general payments during 2025 across 7 reported records.
Exact Sciences Corporation accounted for 36.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.93 | 36.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $38.31 | 28.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.49 | 23.8% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.59 | 11.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $136.32 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $49.93 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.31 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.49 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.49 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 386 | 135 |
| Atorvastatin Calcium | Atorvastatin Calcium | 294 | 119 |
| Omeprazole | Omeprazole | 276 | 94 |
| Losartan Potassium | Losartan Potassium | 266 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 228 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 201 | 78 |
| Metformin Hcl | Metformin Hcl | 177 | 62 |
| Lisinopril | Lisinopril | 175 | 63 |
| Trazodone Hcl | Trazodone Hcl | 150 | 49 |
| Potassium Chloride | Potassium Chloride | 149 | 52 |
| Montelukast Sodium | Montelukast Sodium | 144 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 141 | 54 |
| Furosemide | Furosemide | 134 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 131 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 54 |
| Carvedilol | Carvedilol | 124 | 43 |
| Simvastatin | Simvastatin | 119 | 42 |
| Famotidine | Famotidine | 116 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 49 |
| Glipizide Er | Glipizide | 113 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 57 |
| Metformin Hcl Er | Metformin Hcl | 110 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 45 |
| Januvia | Sitagliptin Phosphate | 106 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 34 |
| Sertraline Hcl | Sertraline Hcl | 96 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 51 |
| Methocarbamol | Methocarbamol | 92 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 37 |
| Eliquis | Apixaban | 84 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 25 |
| Gabapentin | Gabapentin | 76 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 76 | 24 |
| Allopurinol | Allopurinol | 74 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 26 |
| Prednisone | Prednisone | 72 | 62 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 69 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 23 |
| Ozempic | Semaglutide | 67 | 23 |
| Buspirone Hcl | Buspirone Hcl | 63 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 25 |
| Topiramate | Topiramate | 59 | 14 |
| Synthroid | Levothyroxine Sodium | 58 | 21 |
| Promethazine Hcl | Promethazine Hcl | 55 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 15 |
| Glimepiride | Glimepiride | 52 | 22 |
| Donepezil Hcl | Donepezil Hcl | 51 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 21 |
| Atenolol | Atenolol | 49 | 18 |
| Ibuprofen | Ibuprofen | 49 | 19 |
| Mounjaro | Tirzepatide | 49 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 18 |
| Ezetimibe | Ezetimibe | 47 | 15 |
| Meloxicam | Meloxicam | 47 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 16 |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Nystatin | Nystatin | 43 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 13 |
| Meclizine Hcl | Meclizine Hcl | 41 | 23 |
| Ondansetron Odt | Ondansetron | 40 | 29 |
| Azelastine Hcl | Azelastine Hcl | 38 | 22 |
| Spironolactone | Spironolactone | 38 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 38 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | 11 |
| Glipizide | Glipizide | 35 | 12 |
| Jardiance | Empagliflozin | 35 | 11 |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 11 |
| Methylprednisolone | Methylprednisolone | 32 | 31 |
| Azithromycin | Azithromycin | 31 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | 22 |
| Alprazolam | Alprazolam | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | 12 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | 11 |
| Finasteride | Finasteride | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 19 |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 12 |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 12 |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $136.32 · 7 records | Exact Sciences Corporation | Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, Korlym, NURTEC ODT | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error